|
|
With over $2 billion under management, MPM invests in biotechnology, specialty pharma, medical technology, and related companies that provide innovative medical products and requisite services to the healthcare industry, irrespective of geography, stage of development and therapeutic area. MPM closed its fifth venture initiative, the MPM BioVentures V family of funds ('BV5') in 2010. With committed capital just under $300 million, BV5 has a portfolio of 6 companies currently. MPM is actively building the BV5 portfolio and is seeking innovative healthcare opportunities in the U.S. and abroad. In May of 2016, the firm launched a social impact oncology fund, raised in partnership with UBS. The UBS Oncology Impact Fund, with $471 million in committed capital, is an evergreen, crossover fund dedicated to investing in cancer therapeutics. Twenty percent of the committed capital will be dedicated to public equity investments, and the balance to private companies. Since 2018, MPM has donated approximately $7 million of its profits (carried interest) split equally between donations to the American Association of Cancer Research to support research for potential future transformative therapies and donations to the UBS Optimus Foundation to support emerging market access to cancer care. 40
companies have been founded since 2010.
|
